Key Takeaways:
Coiled Therapeutics (AIM:COIL) saw promising clinical results for its lead oncology candidate, AO-252, with the clinical benefit rate doubling to 80% after a change in the dosing regimen.
"The discussion highlights a significant improvement in clinical outcomes," executive chair Dr. Sotirios Stergiopoulos and CEO Sridhar Vempati said in an interview with Proactive.
The sharp increase in the clinical benefit rate, a measure of patients achieving stable disease or better, jumped from 40% to 80%. This improvement followed a strategic shift from a once-daily to a twice-daily dosing schedule for AO-252. The specific trial phase and detailed safety data were not disclosed.
The positive data provides a major boost to the AO-252 program, enhancing the drug's valuation and de-risking its future development path. This result is expected to attract significant investor attention and could lead to a substantial rally in the company's stock price.
The doubling of the benefit rate signals a potentially more effective treatment protocol for this oncology candidate. Investors will now look for the company to announce the next steps in the clinical trial process and a timeline for potential regulatory filings.
This article is for informational purposes only and does not constitute investment advice.
